Positive recommendation moves Januvia closer to Japanese market
This article was originally published in Scrip
Executive Summary
Banyu/Merck & Co's Januvia (sitagliptin) has become the first DPP-4 inhibitor to be recommended for approval in Japan following a positive opinion from a review committee of the ministry of health, labour and welfare.